Cyagen and Taconic Partnered to Receive Permission for Preclinical Studies of Mouse and Rat Models Announcement Cyagen Biosciences, a leading AI-powered CRO company, a pioneer in cell models for research, and custom genetically engineered animals, collaborated with Taconic Biosciences, a well-...
Noom’s New Microdose GLP-1 Program Aims to Tackle Obesity Announcement The Noom, a well-established digital healthcare company focused on chronic disease prevention and encouraging people to live a quality and longer life, launched the Noom microdose GLP-1program, a commendable initiati...
Solving the Commercial Puzzle to Succeed in Cell and Gene Therapies This Year's Challenges to CGT This year witnessed two leading examples of the challenges faced by the cell and gene therapy space, named Bluebird Bio and Sarepta Therapeutics. The two leaders, despite having products on the ma...
Fresenius and Polpharma Entered a Licensing Contract for the Proposed Vedolizumab Biosimilar PB016 Announcement Polpharma Biologics SA, a leading biotechnology company, signed a licensing agreement with Fresenius Kabi for marketing PB016 worldwide except North Africa and the Middle East. PB016...
Kuros Biosciences' New MagnetOs MIS Delivery System Announcement Kuros Biosciences, a known innovator of biologic technologies, completed its first-ever US international case with its new magnetos MIS delivery system. A system features, prefilled, sterile, and single-use delivery system helpfu...
LOTTE BIOLOGICS Bolstered its CDMO Expansion in North America and Asia Announcement Lotte Biologics’ CEO James Park is leveraging its growth as a global Contract development and manufacturing organization (CDMO) company. This year, the company has elevated its CDMO business expansion wit...
Glioblastoma Funding Skyrockets as this Condition Raises Concern Among Nonprofits Announcement According to research, glioblastoma is a life-threatening brain cancer that is difficult to treat. The recent acquisitions by Merck and Jazz Pharmaceuticals, along with the development of innovative ...
New Disease Suspected in Ovarian Cancer Patients Announcement The overall survival (OS) rate for advanced ovarian cancer has consistently been stagnant for almost four decades, because of its steady recurring process. Though patients react safely to the initial chemotherapy and surgeries, it h...
Demetra to Launch a New Global Spine Division by Acquiring Orthofundamentals LLC Announcement Demetra, a well-established and innovative international medical company, and a leader in spacers, biomaterials, and bone cements for PJI infection control and orthopedic applications, has acquired Or...
Mabwell Received a Green Signal for CDH17 Announcement Manwell, an innovative and leading biopharmaceutical company, the pioneer of the entire industry chain, declared that its proprietary CDH17-focused antibody-drug conjugate (ADC), 7MW4911, has received an acceptance from china’s natio...
